WHAT IS CBD?
CBD, or cannabidiol, is a naturally occuring cannabinoid found in the Cannabis sativa plant. Unlike THC (tetrahydrocannabinol), CBD does not produce the intoxicating “high” commonly associated with cannabis. Most commercial CBD is derived from hemp, a variety of Cannabis sativa that federally mandates very low levels of THC (under 0.3%).
Key Takeaways: Understanding CBD and Its Role in Daily Health and Wellness
CBD and THC are both cannabinoids found in Cannabis sativa, but they have different effects on the body. THC is intoxicating and is primarily associated with the euphoric effects of cannabis. CBD is non-intoxicating and interacts with the body’s biological systems through different mechanisms.
CBD interacts with several biological systems and molecular targets, including components of the endocannabinoid system. Research suggests that CBD may influence signaling pathways involved in processes such as pain perception, immune signaling, mood, sleep, and other physiological functions. The effects of CBD are still being studied, and evidence varies depending on the specific application.
The endocannabinoid system is a biological signaling network found throughout the body. It includes endocannabinoids produced by the body, cannabinoid receptors and enzymes involved in producing and breaking down these signaling molecules. The ECS is involved in regulating numerous physiological processes, including sleep, appetite, immune function, mood, memory, and pain perception. For a detailed explanation, read “The Endocannabinoid System”.
Scientific research has investigated CBD in numerous areas, including neurological function, pain perception, inflammation and immune signaling, sleep, anxiety, cardiovascular function and skin-related applications. However, the strength of evidence differs substantially between applications. This Red Mesa CBD Guide provides relevant CBD research summaries and links to underlying studies.
Research is investigating CBD for a variety of potential health and wellness applications, including pain perception, inflammatory processes, sleep, stress and anxiety, neurological function, cardiovascular effects and skin health.
There is no single universally appropriate CBD dose. Research studies have used different amounts depending on the formulation, purpose, study population and route of administration. CBD products should be used according to their labeling, and individuals should consult an appropriate healthcare professional when determining whether CBD is appropriate for them.
CBD safety depends on factors including dose, formulation, individual circumstances, product quality and interactions with medications. Research has identified potential adverse effects and drug-interaction considerations, so CBD should not automatically be considered risk-free simply because it is derived from hemp.
The quality and consistency of CBD can depend on the source material, extraction and refinement processes, manufacturing controls, testing protocols and storage conditions. For companies using CBD as a raw ingredient, documentation such as batch-specific COAs and access to the complete chain of custody can help verify potency, purity and compliance. Red Mesa Science & Refining manufactures cannabinoid raw ingredients under the strict guidance of cGMP and ISO 9001:2015 certification and uses independent ISO 17025-accredited laboratory testing for all finished materials.
Table of Contents
THE HISTORY OF CBD
The understanding of Cannabidiol (CBD) as a derivative of Cannabis Sativa, began with its initial isolation by organic chemist Roger Adams. It was a significant early breakthrough in cannabinoid science, especially given the social stigma associated with Cannabis at the time. In 1963, Israeli organic chemist Dr. Raphael Mechoulam and his research team successfully mapped the exact chemical structure and stereochemistry of CBD at the Hebrew University of Jerusalem. The following year, Mechoulam’s team identified THC as the plant’s primary psychoactive compound, concluding that CBD is a non-intoxicating molecule. This crucial distinction paved the way for therapeutic research. Throughout the late 20th century, scientists increasingly explored CBD’s potential for treating conditions like anxiety, inflammation and epilepsy, even as strict global drug scheduling initially prevented large-scale clinical trials. By the early 2010s, CBD gained significant traction, largely driven by the highly publicized success of CBD-rich formulations in managing severe pediatric seizure disorders, such as Dravet syndrome. Pivoting towards non-intoxicating applications led to industrial hemp reforms and the subsequent expansion of the commercial market. Today, manufacturers have access to a growing supply chain of compliant CBD raw materials, supporting everything from widespread commercial health and wellness products to FDA-approved pharmaceutical treatments, such as Epidiolex for specific seizure disorders. |
IS CBD INTOXICATING OR CONSIDERED A CONTROLLED SUBSTANCE?
CBD is non-intoxicating at all doses studied in humans to date, including at the high pharmaceutical doses used in Epidiolex trials. Unlike THC, CBD does not bind with meaningful affinity at CB1 receptors and does not produce a psychoactive high at any dose.
CBD is not classified as a controlled substance when derived from compliant hemp. At higher doses, some individuals report mild drowsiness, which is distinct from intoxication and is not considered a psychoactive effect.
CBD has been characterized by the WHO as having no abuse or dependence potential and no evidence of public health risk in pure form. CBD may also attenuate THC-associated intoxication through its negative allosteric modulation at CB1 receptors, making it a useful balancing component in full-spectrum formulations.
WHAT DOES CBD DO?
How Does CBD Affect the Body?
Pharmacologically CBD is distinct from THC in that it has low binding affinity at the primary cannabinoid receptors CB1 and CB2. Instead, CBD acts through a wide range of non-cannabinoid molecular targets. Its primary mechanisms include:
- Partial agonism at 5-HT1A serotonin receptors, which mediates its anxiolytic, antidepressant and antinausea effects.
- Agonism at TRPV1 (transient receptor potential vanilloid type 1) channels involved in pain and temperature signaling.
- Activation of PPARgamma receptors, mediating anti-inflammatory and neuroprotective effects.
- Negative allosteric modulation at CB1 receptors, which attenuates THC-induced intoxication.
- Inhibition of FAAH (fatty acid amide hydrolase), increasing endogenous anandamide levels and indirectly enhancing endocannabinoid tone.
- Antagonism at GPR55, a receptor associated with inflammation and cancer cell proliferation.
- Modulation of adenosine signaling through inhibition of the adenosine transporter, contributing to anti-inflammatory and cardioprotective effects.
CBD also enhances GABAergic neurotransmission and exhibits intrinsic antioxidant activity through direct free radical scavenging. It is metabolized primarily via CYP2C19 and CYP3A4.
More than 65 molecular targets for CBD have been identified in the published literature.
What Does the Research Say about CBD?
Cannabidiol (CBD) is the most researched and widely adopted cannabinoid in the world, expanding its use into oils, capsules, beverages, topical formulations, cosmetics and other wellness products.
Published Research:
- 2018 FDA Approval (Epidiolex): The landmark approval of Epidiolex (purified CBD oral solution, GW Pharmaceuticals) for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years and older remains the most significant regulatory milestone in CBD research. Clinical trial data from three pivotal RCTs (N=714 total) demonstrated statistically significant reductions in seizure frequency versus placebo. Epidiolex was subsequently approved for Tuberous Sclerosis Complex (TSC) in 2020.
- 2019 RCT (Anxiety, N=57): A randomized, placebo-controlled crossover trial found that a single oral dose of 300 mg CBD significantly reduced anxiety in simulated public speaking in healthy volunteers, with effects comparable to 5 mg diazepam. (Neuropsychopharmacology, 2019)
- 2024 Systematic Review (Anxiety, 11 RCTs): A comprehensive review of 11 RCTs published between 2013 and 2023 confirmed CBD demonstrates anxiolytic effects through partial agonism at 5-HT1A receptors and negative allosteric modulation at CB1 receptors. (Life, October 2024)
- 2023 RCT (Sleep/CBN+CBD, N=1,793): A large-scale double-blind RCT found formulations containing 15 mg CBD plus 15 mg CBN produced significant improvements in sleep disturbance scores (PROMIS Sleep Disturbance SF 8A), with 56-75% of participants achieving clinically meaningful improvement. (Journal of Cannabis Research, 2023)
Completed Research:
- CUPID Sleep Trial (Woolcock Institute/University of Sydney): Randomized, double-blind, placebo-controlled crossover trial of 30 mg and 300 mg CBD isolate for clinician-diagnosed insomnia disorder using gold-standard polysomnography. Results published in Journal of Sleep Research, 2026.
- Pain Meta-analysis (IASP, 2021): A task force initiated by the International Association for the Study of Pain reviewed 36 RCTs (N=7,217) on cannabinoids for pain. While the review concluded that available evidence does not yet support routine clinical use, it identified CBD as among the most studied compounds and noted that trials to date have been limited by small sample sizes and dosing constraints. Subsequent high-quality CBD pain RCTs are ongoing.
Preclinical Research:
- Extensive preclinical literature supports anti-inflammatory, antioxidant, neuroprotective, and analgesic properties. Animal models demonstrate CBD modulates neuroinflammation relevant to neurodegenerative disease, reduces oxidative stress in cardiac and hepatic tissue, and attenuates pain sensitization via TRPV1 and FAAH inhibition. Antimicrobial activity against MRSA strains has been demonstrated in vitro. Preclinical oncology models show CBD can induce apoptosis in multiple cancer cell lines, though no clinical translation has been confirmed.
Active/Recruiting Research:
- NYU Langone Social Anxiety RCT (NCT05571592): Randomized, placebo-controlled trial of CBD as a treatment for social anxiety disorder. Currently recruiting.
- Randomized, placebo-controlled study of CBD in older adults, currently recruiting through 2028.
WHAT IS THE STANDARD DOSAGE OF CBD?
HOW LONG DOES ONSET TYPICALLY TAKE BY DELIVERY METHOD?
Dependent on formulation and biochemistry of individual. In general:
- Sublingual: ~15-60 mins
- Ingestion: ~1-3 hrs
- Water-Soluble: ~ 15-60 mins Topical: ~ 1hr
- Vape: ~ <10 minutes
HOW LONG DO EFFECTS TYPICALLY LAST
Dependent on formulation and biochemistry of the individual. In general:
- Sublingual: ~4–6 hours duration
- Ingestion: ~4–8 hours duration
- Water-Soluble: ~3–6 hours duration Topical: ~2–6 hours (localized only) Vape~2–4 hours duration
ARE THERE ANY KNOWN CONTRAINDICATIONS, SENSITIVITIES OR POPULATIONS WHO SHOULD USE CAUTION?
CBD has demonstrated a favorable safety profile in published human trials, with no severe adverse events reported at typical consumer doses. That said, responsible product development requires acknowledging the following: CYP450
Drug Interactions: CBD is a potent inhibitor of CYP2C9, CYP2C19, and CYP3A4 liver enzymes. Co-administration with medications metabolized by these pathways, including warfarin, clobazam, valproate, and certain immunosuppressants, can significantly alter plasma drug levels. This interaction is well-documented in Epidiolex clinical trials and represents the most clinically significant safety signal for CBD.
Pregnancy and Breastfeeding: Not recommended due to insufficient human safety data.
Liver Enzyme Elevation: High-dose CBD (pharmaceutical range) has been associated with transient liver enzyme elevations. At consumer supplement doses, this has not been a documented concern.
CNS Depressant Combinations: Additive sedation is possible when combined with alcohol, benzodiazepines, or other sedating substances.
As with any supplement, individuals with underlying health conditions or those taking prescription medications should consult a licensed healthcare provider before use.
ARE THE EFFECTS OF CBD COMPARABLE TO ANY FAMILIAR OVER THE COUNTER AIDS?
The calming and settling experience of CBD at typical wellness doses is often compared to the gentle relaxation associated with L-theanine supplements or chamomile-based sleep and calm products, a noticeable easing of tension without sedation or impairment. Consumers familiar with magnesium glycinate for stress and sleep support often find CBD comparable in character. For those who use adaptogenic products like ashwagandha for stress resilience, CBD occupies a similar space in a daily wellness routine.
The important distinction from OTC sleep aids containing diphenhydramine or doxylamine is that CBD does not produce the heavy next-morning grogginess associated with those compounds.
WHICH CBD FORMAT SHOULD I USE?
Consider CBD Isolate, Distillate or Water Soluble to Achieve Formulation Goals
WHAT CBD BLENDS PERFORM BEST?
CBD functions as an excellent base and complement in multi-cannabinoid formulations due to its broad receptor activity and well-established safety profile.
- CBD + CBN is among the most commercially validated pairings, supported by published human trial data, particularly for nighttime and sleep applications.
- CBD + CBG is a strong pairing for daytime focus, anti-inflammatory, and recovery formulations, as CBG adds adrenergic and distinct receptor activity, broadening the overall effect profile.
- CBD + THC at varying ratios is the most studied combination in clinical literature, where CBD is known to attenuate THC-associated anxiety and intoxication while preserving analgesic and sedative benefits.
- CBD also pairs well with minor cannabinoids like CBC for anti-inflammatory applications and CBDV for neurological wellness formulations.
In all cases, the optimal ratio and pairing depend on the desired consumer outcome and delivery format, which is why CBD appears across the full portfolio of product categories in both the hemp and licensed cannabis markets.
CHOOSING THE IDEAL MANUFACTURING PARTNER
Red Mesa Science & Refining - Your Strategic Source for CBD, CBG, CBN and other Minor Cannabinoid Raw Ingredients
Red Mesa Science & Refining – Your Strategic Source for CBD, CBG, CBN and other Minor Cannabinoid Raw Ingredients
Red Mesa Science & Refining is the premier globally recognized large-scale producer of hemp-derived CBD, CBG, CBN & other Cannabinoid Isolates, Water Soluble, Distillates, Crystal Resistant Distillates and Botanically Refined raw ingredients. Red Mesa manufactures its products within its 50,000 sq. ft. FDA-registered food facility, under the guidance of ISO 9001:2015 certification and cGMP.
Maintaining rigorous self-imposed standards to exceed industry practices, Red Mesa has earned a reputation as an ethical and trusted manufacturer dedicated to professionalism, quality, safety, reliability and transparency. This commitment ensures that customer expectations are met and satisfaction is achieved.
Contact our experts to discuss your formulation requirements and how to choose the best CBD raw ingredient to achieve your formulation goals.
